☆ 4.1 Meeting Abstract

Nilotinib (NIL) vs. NIL Plus Pegylated Interferon alpha2B (IFN) Induction and NIL or IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1+Chronic Myeloid Leukemia (CML) Patients (PTS) in Chronic Phase

ONCOLOGY RESEARCH AND TREATMENT (2020)

Add to Collection

Journal

ONCOLOGY RESEARCH AND TREATMENT
Volume 43, Issue -, Pages 104-104

Publisher

KARGER

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.